CDNA · 6 developments mapped · last assessed 2026-09-20
Market Ontology has mapped 6 macro, policy, and market developments to Codiak BioSciences, Inc. since 2026-09-19. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Last close
Unavailable
No published quote
Market cap
Unavailable
Equity value
Diluted shares
Unavailable
Latest reported
Sector
Unavailable
Listing
Unavailable
Filings
Unavailable
No published filing
Valuation
No validated run has been published for CDNA yet, so no modelled value is shown. The CDNA valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run CDNA on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
A validated filed-statement snapshot has not been published for CDNA. Missing data is not estimated or replaced with scenario assumptions.
Current case
Open question
Twist Bioscience partners with Eli Lilly on TuneLab AI discovery
Increased competitive pressure in synthetic biology and antibody discovery services, potential for market share shifts.
· Moves market share in synthetic biology tools, pricing power for services
What changed, by assumption
Market share in synthetic biology tools
2026-09-19Twist Bioscience partners with Eli Lilly on TuneLab AI discovery
Market share in synthetic biology services
2026-09-19Twist Bioscience Partners with Eli Lilly on AI Drug Discovery Platform
Investor sentiment
2026-09-19Twist Bioscience Partners with Eli Lilly on AI-Powered TuneLab Platform
Future partnership potential
2026-09-20Twist Bioscience shares gain 31% on Eli Lilly AI drug discovery pact
Market perception of biotech innovation
2026-09-19Twist Bioscience partners with Eli Lilly on AI-driven TuneLab drug discovery